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1. Abstract
Drug resistance remains a major problem for the treatment of HIV. Resistance can occur
due to mutations that were present before treatment starts or due to mutations that occur
during treatment. The relative importance of these two sources is unknown. Resistance can
also be transmitted between patients, but this process is not considered in the current study.
We study three diﬀerent situations in which HIV drug resistance may evolve: starting triple-
drug therapy, treatment with a single dose of nevirapine and interruption of treatment. For
each of these three cases good data are available from literature, which allows us to estimate
the probability that resistance evolves from standing genetic variation. Depending on the
treatment we ﬁnd probabilities of the evolution of drug resistance due to standing genetic
variation between 0 and 39%. For patients who start triple-drug combination therapy, we
ﬁnd that drug resistance evolves from standing genetic variation in approximately 6% of the
patients. We use a population-dynamic and population-genetic model to understand the
observations and to estimate important evolutionary parameters under the assumption that
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treatment failure is caused by the ﬁxation of a single drug resistance mutation. We ﬁnd
that both, the eﬀective population size of the virus before treatment, and the ﬁtness of the
resistant mutant during treatment, are key-parameters which determine the probability that
resistance evolves from standing genetic variation. Importantly, clinical data indicate that
both of these parameters can be manipulated by the kind of treatment that is used.
2. Author summary
For HIV patients who are treated with antiretroviral drugs, treatment usually works well.
However, the virus can, and sometimes does, become resistant against one or more drugs.
HIV drug resistance results from the acquisition of speciﬁc and well known mutations. It
is currently unknown whether drug resistance mutations usually stem from standing genetic
variation, i.e., they were already present at low frequency before treatment started, or whether
they tend to occur during treatment. In the current manuscript, I make use of several large
datasets and evolutionary modeling to estimate the probability that drug resistance mutations
are present before treatment starts and lead to viral failure. I ﬁnd that for the most common
type of treatment with a combination of three drugs, drug resistance evolves from pre-existing
mutations in 6% of the patients. With other types of treatment, this probability varies from
0 to 39%. I conclude that there is room for improvement in preventing the evolution of drug
resistance from pre-existing mutations.
3. Introduction
For most HIV patients, treatment with modern antiretroviral therapy leads to a rapid
decline of viral load (VL) of several orders of magnitude. However, when the virus acquires
resistance to one or more drugs, treatment can fail. It is still an open question whether the
mutations responsible for resistance originate usually from standing genetic variation (also
referred to as pre-existing mutations or minority variants), or from new mutations which
occur during therapy. In fact, there is no single biological system for which the relative role
of pre-existing and new mutations is well known [1]. Another important open question is
whether multiple simultaneous mutations are needed for the viral population to be able to
grow during therapy, or whether a single mutation allows escape. Amongst evolutionary
biologists, it is commonly assumed that therapy with multiple drugs works so well because
the virus needs multiple mutations to escape, which is unlikely to happen. However, patient
data show that patients often fail therapy with a single resistance mutation [5, 6] which
suggests that a single mutation can increase the ﬁtness of the virus to above 1, even though
the virus is still susceptible to two of the drugs in the treatment. In this scenario, the main
beneﬁt of combination therapy over monotherapy would be that combination therapy reduces
the population size of the virus and therefore the probability that mutations occur. In this
study we will analyze patient data under the assumption that a single mutation can lead to
virologic failure and thereby propose an alternative view on the evolution of drug resistance
during multi-drug therapy.
We will look at the establishment of drug resistance mutations in three diﬀerent situations:
(1) when triple-drug therapy (ART) is started for the ﬁrst time, (2) when pregnant women are
treated with a single dose of nevirapine (sdNVP) to prevent infection of the baby during birth
and (3) when ART is interrupted and restarted. We will argue that standing genetic variation
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mutations become established in each of these cases can be understood by using a simple
population genetic model.
For readers who are not familiar with HIV, it is important to know that the genotype-
phenotype map for drug resistance in HIV is very well known. Lists of the important re-
sistance mutations for each drug are published (e.g., in the International AIDS SocietyUSA
drug resistance mutations list, [2], so that doctors can compare the genotype of the virus
of a patient before treatment with this list to decide which drugs to prescribe. The aim
of treatment is to achieve viral suppression. If treatment fails, i.e., the viral load stays or
becomes higher than a predetermined threshold, such as 50/ml, despite adherence to the
regimen, a second genotypic test will be performed to see whether the virus has acquired
new resistance mutations. Since the second half of the 1990s, treatment is usually with a
combination of three drugs, which are chosen such that mutations which confer resistance
against one of the drugs do not confer cross-resistance against the other two drugs. Soon
after its introduction, it became clear that triple-drug therapy was an enormous success and
saved the lives of many HIV patients [3]. One reason why therapy with three drugs works
better than treatment with one or two drugs is that the rate at which resistance evolves is
slower when patients are treated with three drugs [4]. It is commonly thought that resistance
does not evolve in patients on triple-drug therapy because it would require a viral particle
to acquire three mutations at the same time. However, in patients who are treated with
triple-drug therapy, it is often observed that resistance against one of the drugs evolves, at
least initially. Data from several cohort studies in diﬀerent parts of the world, such as from
Canada [5] and the UK (UK CHIC cohort study, [6] clearly show that in most patients who
fail therapy due to resistance, the virus is resistant against one of the drugs and almost never
against all three. The UK study, for example, reports that out of 4306 patients who started
therapy between 1996 and 2003, after two years of therapy, 13% have drug resistance. A
majority of the patients with drug resistance (7%) have resistance against just one of the
drugs. Less than half of the patients (6%) have resistance against more than one class of
drugs and a only small number of patients (1%) have resistance against 3 classes of drugs,
even though all patients of this cohort were treated with three classes of drugs. These data
show that treatment can fail due to resistance against one of the drugs in a regimen. In such
cases, it may be that the other two drugs cannot keep the VL completely suppressed, even
though they still work. The viruses that have acquired resistance against two or three classes
of drugs may have acquired these mutations at the same time or they may have acquired
them one by one. For now, we will assume the latter and focus only on the probability of
acquiring the ﬁrst drug resistance mutation (DRM).
For many common drugs, especially reverse transcriptase inhibitors, a single mutation can
confer resistance against the drug and only a small number of mutations is responsible for
resistance in most patients. For example, resistance against the drug nevirapine is almost
always due to one of two amino acid changes, namely K103N or Y181C in the reverse-
transcriptase gene [7]. Because of the importance of a small number of mutations, several
studies have investigated whether these mutations are present in untreated patients due
to transmitted drug resistance or due to spontaneous mutation. Recent studies have used
allele-speciﬁc PCR and related methods to determine the frequency of several important
mutations in untreated patients. Low-frequency drug resistance mutations (DRMs), likely
due to spontaneous mutation (and not transmitted from other patients) were detected in up
to 40% of patients (see [8] for an overview). The detection of drug resistance mutations in4P L E U N I S . P E N N I N G S
untreated patients, together with the knowledge that a single mutation can confer resistance
against a drug and allow viral escape, suggest that pre-existing resistance mutations (or
standing genetic variation in the population genetic jargon) may play an important role in
the evolution of drug resistance in HIV.
Throughout the paper, we will assume that a single mutation can allow viral escape and we
focus on the probability that such a ﬁrst drug resistance mutation becomes established (i.e.,
it reaches such a frequency that it can be expected to become the majority variant unless
treatment is stopped or changed quickly). What happens after a ﬁrst mutation has become
established, or how fast such an established mutation wanes in the absence of treatment are
important questions, but they fall outside the scope of this study. In this paper, ‘triple-drug
therapy” and ART refer to treatment with two drugs of the class NRTI plus either an NNRTI
or an unboosted PI (for a list of abbreviations in the paper, see Table 2). The results are
likely to be diﬀerent for other drug combinations.
Starting therapy. When a patient starts therapy for the ﬁrst time, one would expect that
there should be a substantial probability that drug resistance evolves due to pre-existing
DRMs. Indeed, recent studies have shown that the presence of drug resistance mutations
at low frequency (<1%) increases the risk that treatment fails (e.g., [9],[10], [7], see [11]
for a review). However, the situation is not as simple as one may hope: even if no pre-
existing DRMs can be detected, resistance mutations may become established quickly, and
even if DRMs are detected, treatment is still successful in the majority of patients. We will
attempt to understand those observations using population genetic theory. Other authors
have looked at the question of pre-existing DRMs previously (e.g., [12], [13]), however, it
is worth reconsidering the topic. First of all, we now have a wealth of data available for
pre-existing DRMs and the establishment of drug resistance mutations in HIV patients, and
secondly, we now have a better theoretical framework to consider the role of standing genetic
variation for adaptation [14].
Prevention of mother to child transmission (PMTCT). Pregnant women in low resource
settings are often treated with a single dose of the non-nucleoside reverse transcriptase in-
hibitor neverapine when labor starts. Single dose nevirapine (sdNVP) is the cheapest and
simplest way to reduce the probability of mother-to-child-transmission, but it is shown to
lead to the establishment of drug resistance mutations in the mothers and the babies. In a
meta-analysis, [15] found that, in 7 diﬀerent studies, on average 44% of the patients treated
with sdNVP had detectable NVP resistance mutation several weeks after the treatment. The
presence of such mutations makes future treatment of these women harder [16]. To avoid the
establishment of resistance mutations, several alternative strategies are used in combination
with sdNVP. We will use the same population genetic framework as in the other two cases
to try to understand why sdNVP leads to establishment of resistance mutations in so many
patients, and how this can be avoided. In the current study we will only focus on the proba-
bility that NVP resistance mutations become established during treatment for PMTCT. The
issue of how these mutations wane and possibly resurface when treatment is started again is
important and interesting but falls outside the scope of the current paper.
Treatment interruptions. It was long suspected that treatment interruptions lead to drug
resistance. Indeed, cohort studies show that treatment interruptions due to non-adherence
are associated with faster accumulation of drug resistance mutations ([17, 18, 19]. Clear
evidence that treatment interruptions of at least a couple of weeks lead to the establishment
of resistance mutations comes from clinical trials (e.g., [20, 21, 22] which were done in a timeSTANDING GENETIC VARIATION AND THE EVOLUTION OF DRUG RESISTANCE IN HIV 5
when it was believed that treatment interruptions may be beneﬁcial for patients. In 2006 the
SMART trial was stopped because treatment interruptions were shown to have a negative
eﬀect on patients’ health [23]. However, treatment interruptions still occur, for example,
when a patient is forgetful or is unable to purchase drugs due to ﬁnancial or logistic barriers.
It is important to understand how treatment interruptions lead to resistance and whether
this eﬀect can be avoided.
The main idea that currently governs the thinking about treatment interruptions and re-
sistance is that insuﬃcient drug-levels allow for replication and, at the same time, select for
resistance (e.g., [24, 25, 18]. This eﬀect is aggravated when drugs that are part of combi-
nation therapy have very diﬀerent half-lifes, so that interrupting combination therapy can
result in eﬀective monotherapy. It is generally believed that this “tail of monotherapy” is the
main reason why treatment interruptions lead to drug resistance. However, several observa-
tions are not compatible with the “tail” hypothesis. For example, Fox et al ([25]) found no
signiﬁcant diﬀerence in the number of resistance mutations after simultaneous, “staggered”
or “switched” treatment interruptions in patients from the SMART trial (a “staggered” stop
means that the long half-life drug is interrupted several days before the other drugs and a
“switched” stop means that before interrupting, patients switch to a regimen with only short
half-life drugs). In addition, the “tail” hypothesis fails to explain why treatment interruptions
increase the risk of resistance in patients on protease inhibitor-based (PI) regimens which do
not have long half-lifes [26, 20, 27, 28, 29, 30]. Another explanation is therefore needed to
understand the observed patterns.
When treatment is interrupted, the viral load rapidly increases until it has reached its
original level after approximately four weeks [31]. Basic population genetics tells us that
such population growth also leads to an increase in the probability that DRMs are present.
When treatment is started again, selection may work on such pre-existing mutations, which
provides a simple explanation for how treatment interruptions lead to the establishment of
resistance mutations.
In this paper we will attempt to explain the observed patterns by considering selection
on pre-existing variation and selection on new mutations. It is worth noting here that pre-
existing does not necessarily mean old, such a mutation may have originated just a day
before the start of treatment. Throughout the paper, we use a mathematical model for
adaptation from standing genetic variation which we developed previously [14] and forward-
in-time, individual-based computer simulations. The model captures mutation, drift and
selection, including changing selection pressures (due to stopping and starting of therapy)
which lead to changes in population size. Because we only focus on the establishment of
the ﬁrst drug resistance mutation, we can ignore epistatic interactions between diﬀerent
drug-resistance mutations and recombination. In each of the three cases of interest, we use
published data on the percentage of patients with established drug resistance mutations to
estimate important parameter values (for starting ART or sdNVP) and to predict outcomes
(for treatment interruptions).
4. Model
Model, assumptions and ﬁxation probability of a drug resistance mutation The model we
use in this paper describes the population dynamics and population genetics of a panmictic
viral population in a single patient. Details of the model can be found in the supplementary
material. We assume that as long as the patient is not treated, the viral population will6P L E U N I S . P E N N I N G S
be stable at population size Nu (u for untreated). Drugs reduce the ﬁtness of the wildtype
virus to below 1 so that the population will shrink. We assume that there is a large reservoir
of latently infected cells of which a ﬁxed number (NLAT)b e c o m ea c t i v a t e dp e rg e n e r a t i o n ,
so that the virus can not die out. Drug resistant virus can be created by mutation and is
assumed to be resistant against one of the drugs in the treatment regimen. If the patient
is not taking drugs, the drug resistant virus is less ﬁt than the wildtype by a factor Crel
(relative cost of the resistant virus), but if the patient is taking drugs, the resistant virus has
aﬁ t n e s st h a ti sh i g h e rt h a n1( Fm ART > 1), whereas the wildtype has a ﬁtness lower than
1( Fwt ART < 1). In reality, there may also be resistance mutations that confer resistance
against one of the drugs, but that do not lead to a ﬁtness higher than 1. Such mutations will
quickly die out and can safely be ignored in the model. Throughout the paper we focus on
the the processes that allow a ﬁrst major drug resistance mutation to become established in
the patient. Patients are assumed to be ART-naive and have no transmitted drug resistance.
Evolutionary biologists have long known that most mutations will be lost by genetic drift
even if they confer a ﬁtness beneﬁt [32]. This is also true for drug resistance mutations
(DRMs) in patients on anti-retroviral therapy, although it is all too often ignored in drug
resistance studies. The clinical relevance of this old result has recently become very clear.
It was found in several studies that even though low frequency DRMs increase the risk of
treatment failure and establishment of drug resistance, the majority of patients with detected
low frequency DRMs will respond well to treatment [7]. This result shows that DRMs can
die out, even if they have reached frequencies high enough to be detected. The reason is
probably that most viral particles will not infect any new cells and produce no new viral
particles, even if, on average, they produce more than 1.
The probability that a DRM becomes established in the patient depends on the number
of copies that are present, the average number of oﬀspring of the drug resistant particles
and the variance in oﬀspring number. Traditionally, ﬁxation or establishment probabilities
are calculated using the relative ﬁtness diﬀerence between the mutant and the wildtype,
but in the case of HIV it is more useful to use the ﬁtness of the mutant virus to calculate
its establishment probability. The reason is that anti-retroviral therapy works so well that
wildtype ﬁtness may be very low (much lower than 1). In such case ﬁtness of the mutant
may not be related to the ﬁtness of the wildtype and because the wildtype cannot grow,
the two types do not compete for resources. In other words, the mutant can occupy a niche
that is not occupied by the wildtype. In those cases, and as long as Fm ART − 1 << 1, the
establishment probability of the mutant will be approximately Pest ≈
2(FmART−1)
σ2 where σ2 is
the variance in oﬀspring number. In the simulations and throughout this paper, we use the
variance eﬀective population size, in which case one can assume that σ2 =1 ,s ot h a t
(1) Pest ≈ 2( Fm ART − 1)
Note that by setting σ2 = 1, we ignore all mutations which occur in virus which is not part
of the eﬀective population size. The establishment probability of a mutation in a random
viral particle (e.g., when observed in a patient) may be much lower. It is important to realize
that if the establishment probability of a DRM depends on its absolute ﬁtness, anything that
reduces its ﬁtness will reduce the establishment probability. For example, if a drug that is
added to a regime reduces ﬁtness of both wildtype and resistant virus, then it will reduce
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if the eﬀect of the added drug on wildtype and resistant virus is exactly the same. Similarly,
if the immune system works well, this may also reduce the probability of establishment.
In most population genetics models, the focus is on the ﬁxation probability, rather than
the establishment probability of a mutation. And in many models, if a mutation becomes
established, it will go to ﬁxation. However, if selection pressures change, establishment does
not necessarily lead to ﬁxation. This is especially clear when we will later consider the eﬀect
of a single-dose of nevirapine. A few weeks after a single dose of nevirapine, nevirapine
resistance mutations can be detected in a large proportion of patients, but these mutations
may never take over the whole viral population, because the treatment duration is very short
and wildtype virus will quickly become a majority again (see for example, [16]). In fact, the
standard results on ﬁxation probability [32] are really results on establishment probabilities,
so we can use them without problems.
Psgv vs. Pnew. For drug resistance to evolve, the viral population needs viral particles
that carry drug resistance mutations. Such particles may already be present before treatment
is started. To denote this possibility we use Psgv or the probability that drug resistance
establishes from the standing genetic variation. If the mutation is not already present,
or if was present but was subsequently lost, then the viral population has to wait for a
new mutation to occur and become established. We denote this possibility as Pnew,o rt h e
probability that resistance evolves due to new mutations. In the latter case, we have to
indicate a time window, such as per year or per generation.
The goal of this study is to understand and, albeit roughly, quantify Pnew and Psgv for HIV
drug resistance in patients on triple-drug regimes (consisting of an NNRTI or an unboosted
PI plus two NRTI’s) and in patients who are treated with single dose nevirapine.
5. Results
5.1. Starting standard therapy. When a patient starts anti-retroviral therapy for the ﬁrst
time, the viral population in that patient will move from an equilibrium without drugs to an
equilibrium with drugs. At the pre-treatment equilibrium, the viral population size will at its
equilibrium level (Nu), and resistance mutations are expected to be at mutation-selection-
drift equilibrium, where most mutations will be present at very low frequencies (see, e.g.,
[7]). Note that mutation-selection-drift equilibrium is reached quickly for mutations that are
very costly to the virus. So even though it may take years for neutral diversity to reach an
equilibrium level in an HIV patient [33], important drug resistance mutations which are 5 or
10% less ﬁt than the wildtype are expected to reach their (dynamic) equilibrium in weeks or
months.
Standard population genetic theory predicts that the average frequency of a resistance
mutation is equal to the mutation rate (µ,p e rv i r a lp a r t i c l ea n dp e rr e p l i c a t i o n )d i v i d e d
by the relative cost (Crel)o ft h er e s i s t a n c em u t a t i o n ,t h o u g hd r i f tc a u s e sa c t u a lf r e q u e n c i e s
to vary greatly between diﬀerent time points and between patients (see also [34]). Even
though the average frequency is independent of the population size, in larger populations,
it is more likely that DRMs are present and the absolute number of drug resistant particles
will, naturally, be higher. When treatment starts, resistance mutations will confer a ﬁtness
beneﬁt to the virus and they can (but are not guaranteed to) increase in frequency and
become established. The probability that this happens depends on the number of resistant
particles in the population and on the establishment probability of a mutation that is present
in a single particle. In [14] we derived formulas to calculate the probability that adaptation8P L E U N I S . P E N N I N G S
to a new environment happens from the standing genetic variation (Psgv). We will use the
approximate equation 8 in [14]:
(2) Psgv ≈ 1 − (1 +
Fm ART − 1
Crel
)
−2µNu
It is also possible to use the the number of resistant particles in a patient (B), if this
is known, and the ﬁtness of these copies (in the environment with drugs) to calculate the
probability that a resistance mutation becomes established:
(3) Psgv =1− (1 − Pest)
B
where we use the probability that all copies of the resistance mutation die out to calculate
the probability that at least one survives. The probability that resistance mutations become
established increases with the number of copies of resistant virus and the probability that
any one of these survives.
Evolution of resistance during therapy. If resistance did not evolve from standing
genetic variation, it may evolve due to new mutations. The probability that this happens in
ag i v e ny e a rw i l ld e p e n do nt h en u m b e ro fg e n e r a t i o n s( G)i nay e a r ,t h em u t a t i o nr a t e( µ),
the eﬀective population size during antiretroviral treatment (NART)a n dt h ee s t a b l i s h m e n t
probability of a mutation (Pest). In principle, the establishment probability during therapy
may not be the same as in the very beginning of therapy, for example because the number of
available cells which a particle can infect could be diﬀerent. However, throughout this paper
we will assume that Pest depends only on the kind of therapy and not on how long a patient
has been treated. Using a poisson approximation, we ﬁnd that the per year probability that
resistance evolves is
(4) Pnew =1− exp (−GN ART µP est)
It is debated whether during therapy, there is ongoing replication or whether a reservoir
of latently infected cells is entirely responsible to residual viremia. If the reservoir reﬂects
the composition of the viral population before treatment, then the expected frequency of the
resistance mutation in the reservoir would be
µ
Crel.I f t h e n u m b e r o f l a t e n t l y i n f e c t e d c e l l s
that become activated every generation is NLAT,t h e nt h ee x p e c t e dn u m b e ro fa c t i v a t e dc e l l s
with resistant virus would be
NLAT µ
Crel . The per year probability that resistance evolves due to
activated cells from the reservoir would be
(5) Pnew =1− exp (
−GN LAT µP est
Crel
)
It is also possible that there is ongoing replication, but that the reservoir also plays a role
at the same time, so that the reality will be reﬂected best by a combination of equations
4 and 5. Note that NART and NLAT are both eﬀective population sizes, and may be much
lower than the census population sizes.
Comparison with data and parameter estimation Published data show that the rate
of evolution of drug resistance is roughly constant over long times (see for example the study
by [6], in which patients were followed for up to eight years). This ﬁts with expectations if
NART and Pest remain constant so that Pnew stays constant. However, several studies show
that the probability that resistance mutations become established is higher in the ﬁrst yearSTANDING GENETIC VARIATION AND THE EVOLUTION OF DRUG RESISTANCE IN HIV 9
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Figure 1. The probability that resistance is detected for the ﬁrst time in the ﬁrst,
second or third year of treatment, given that it was not detected until then. The bars
are the estimates from the Margot et al ([35]) dataset. The red dashed area reﬂects
the inferred probability that resistance mutations from standing genetic variation
become established. The grey squares are values calculated using equations 2 and 4.
The red circles are estimated from 1000 simulations. Parameters as in table 1.
of therapy, as compared to later years. This can be seen, for example, in a study on a
large cohort in British Columbia, especially when one considers the most adherent group of
patients (ﬁgure 2 in [36], see also [17]). A similar eﬀect is seen in [11] when one considers the
patients with pre-existing DRMs. This eﬀect, that resistance is more likely to evolve in the
ﬁrst year of therapy as compared to later years, can be easily explained by standing genetic
variation.
Under the assumption that Pnew is indeed constant, we can use published data to estimate
both Pnew and Psgv.M a r g o te ta l[ 3 5 ]r e p o r t e dt h en u m b e ro fp a t i e n t si nw h i c hr e s i s t a n c ew a s
detected in the ﬁrst, second and third year after treatment initiation in a cohort of patients
who were treated with NNRTI-based ART. The reported data show that the probability that
resistance was detected in the ﬁrst year was 9.5%, whereas in the second and third year it was
only 3.7% (see supplementary material for details on how this was estimated). The diﬀerence
of 5.8% is likely due to standing genetic variation at the start of therapy.
We will use the estimates for Pnew (0.037 per year) and Psgv (0.058) from [35], in combina-
tion with other, published, estimates to get a rough estimate of the important evolutionary
parameters. First of all, we will assume that the mutation rate from one nucleotide to a
speciﬁc other nucleotide is 10−5 [37], so that if there are ﬁve main resistance mutations for a
given drug combination, the total mutation rate is approximately 5×10−5.F o rt h er e m a i n d e r
of the paper, we will only use this total mutation rate. If the mutation rate would be higher
(lower) than our assumption, the estimated population sizes would be lower (higher) than
our estimates.
We know that the important drug resistance mutations are at least somewhat costly for
the virus. Their cost, Crel,h a sb e e ne s t i m a t e df o rs e v e r a ld r u gr e s i s t a n c em u t a t i o n s ,b o t h
in vivo and in vitro (for an overview on resistance mutations in the reverse transcriptase
gene see [38]). For example, [39] ﬁnd that the relative cost of resistance mutation M184V is
approximately 0.04 − 0.08. Wang et al [40] estimate a cost of 0.01 − 0.04 for K103N, which10 PLEUNI S. PENNINGS
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Figure 2. 2a. Continuous line: combinations of population size before treatment
(Nu) and ﬁtness of mutant virus during therapy (FmART that lead to the observed
probability that resistance mutations from standing genetic variation become estab-
lished (Psgv =0 .058). Dashed line: combinations of population size during treatment
(NART) and ﬁtness of mutant virus during therapy (FmART that lead to the observed
probability that resistance mutations from standing genetic variation become estab-
lished (Psgv =0 .058). Open dot: Nu = 2000 and FmART =1 .017, closed dot:
NART = 108, FmART =1 .017. 2b. Probability that a patient has any pre-existing
DRMs before the start of therapy for diﬀerent population sizes, and µ =5× 10−5.
Open dot: Nu = 2000
is the most common NNRTI resistance mutation. Other studies were not able to detect any
cost of K103N, but given its low frequency in untreated patients [7], it seems likely that it
is associated with a signiﬁcant cost. In this paper we will use an average cost of 0.05 for all
mutations.
Given the cost, the mutation rate, Psgv and Pnew,a n du s i n gt h ea s s u m p t i o nt h a tt h e r ea r e
200 HIV generations in a year [41], we can ﬁnd the combinations of Nu, NART and Fm ART
that are compatible with the data (shown in ﬁgure 2). Estimates for the eﬀective population
size in untreated patients range from 103 [42] to 105 [43]. We know that a large proportion
of untreated patients carries low frequency drug resistance mutations, but not all patients,
which gives us some additional information about the population size in an untreated patient
(see ﬁgure 2b). If we choose a value of Nu of 2 × 103,t h e nw eﬁ n dt h a ta b o u th a l fo ft h e
patients should carry pre-existing DRMs. This is somewhat higher than what is usually
detected, but that can be due in part to the limits of detection of current tests [8]. An
overview of the parameter estimates that were used in the simulations and for analytical
predictions can be found in table 1.STANDING GENETIC VARIATION AND THE EVOLUTION OF DRUG RESISTANCE IN HIV 11
Given our choice of Nu,w eﬁ n dt h a tFm ART must be approximately 1.017, leading to
Pest ≈ 0.034. Under the assumption Pest stays the same during treatment, the Margot et al
data are compatible with a 18-fold reduction of the eﬀective population size due to therapy,
to an eﬀective population size of NART ≈ 108. Note however, that the estimate of a 18-fold
reduction depends heavily on the assumption that Crel =0 .05. For example, had we assumed
a1 0 %c o s t ,t h e nt h ee s t i m a t e dr e d u c t i o nw o u l dh a v eb e e n3 7 - f o l d ,a n df o ra1 %c o s t ,t h e
reduction would have been only 4-fold. The reason is that if we assume that costs are high,
then we must also assume that the mutant ﬁtness (Fm ART)i sr e l a t i v e l yh i g h ,i no r d e rt o
ﬁnd Psgv =0 .06, and if Fm ART is high, NART must be low, to explain Pnew =0 .037.
If the evolution of resistance during therapy is not due to ongoing replication, but due
to continuous activation of latent cells, then, under the assumption that Crel =0 .05, the
eﬀective number of cells (NLAT)m u s tb ea p p r o x i m a t e l y5p e rg e n e r a t i o n . T h i sm e a n sa
reduction of eﬀective population size of almost 400-fold. However, it is not so clear whether
in this case the word “population size” should still be used, because the number 5 is not an
estimate of the size of the reservoir, but an estimate of the eﬀective size of the part of the
reservoir that is reactivated every generation.
The result that the frequency of resistance mutations in the reservoir depends on their
ﬁtness cost (
µ
Crel), whereas the cost does not play a role for new mutations due to ongoing
replication, could be harnessed to estimate the relative importance of the reservoir. If the
reservoir is the most important source of resistance mutations during therapy, then the same
set of mutations should be found in patients whose virus acquires resistance quickly after the
start of therapy and in those who acquire mutations during therapy. However, if ongoing
replication is the source of resistance mutations during therapy, then mutations with a high
cost in the absence of drugs should occur relatively more often during therapy than quickly
after therapy is started.
The data and the results from simulations and predictions (using equations 2 and 4) are
shown in ﬁgure 1. The percentage of patients with resistance after one year is lower in the
simulations than in the analytical predictions, because in the simulations, it takes time for a
mutation to increase in frequency and be detected. We assume that it is detected as soon as
it is more frequent than the wildtype, the result is that in the simulations (and probably in
reality) Pnew is lower in the ﬁrst year than in the other two years. It is unclear how large this
eﬀect is in reality, but it means that the 6% we ﬁnd is a conservative estimate of the role of
standing genetic variation. If it would take 3 months for a mutation to increase in frequency
and become detected, then Pnew in year 1 would be 75% of its value in the later years, and
Psgv would be approximately 7% in stead of 6%.
5.2. Single-dose nevirapine for prevention of mother-to-child-transmission. As i n -
gle dose of nevirapine (sdNVP) just before labor starts reduces the risk that a mother trans-
mits HIV to her baby at birth, but leads to high levels of resistance in many women. Because
of the long half life of nevirapine, even a single dose lasts at least a few days. However, this
is a very short amount of time (only a few HIV generations) so that probably most or all
detected NVP resistance mutations are due to standing genetic variation.
Because it is known that sdNVP can lead to the establishment of resistance mutations,
and also to further reduce the risk that the baby becomes infected with HIV, several dif-
ferent treatment strategies are being used. In this study, we focus only on those strategies
that include a single dose of nevirapine (and exclude, for example, pregnancy limited triple-
drug therapy). Basically, sdNVP can be combined with either a short course of zidovudine12 PLEUNI S. PENNINGS
Table 1. Parameter values for analytical predictions and computer simulations.
Parameter Value Explanation
Values roughly based on lit-
erature
µ 5*10-5 Mutation rate to resistant genotype
Nu 2000 Eﬀective population size in untreated patient
Crel 0.05 Relative cost of mutant in absence of therapy
FwtART = FwtNVP 0.5 Absolute ﬁtness of wildtype during therapy
G 200 Number of HIV generations per year
Values estimated in current
study
NART 108 Eﬀective population size in patient on ART
NLAT 5 Number of activated latent cells in patient on ART
NZDV 1000 Eﬀective population size in patient on ZDV monotherapy
Fwtu 1.62 Absolute ﬁtness of wildtype in absence of therapy (determines growth rate
during treatment interruption)
Fmu 1.54 Absolute ﬁtness of resistant mutant in absence of therapy
FmART 1.017 Absolute ﬁtness of resistant mutant during ART
FmNVP 1.54 Absolute ﬁtness of resistant mutant during NVP therapy
FmNVP/PP 1.025 Absolute ﬁtness of resistant mutant during NVP/PP therapy
Table 2. Abbreviations.
Abbreviation Explanation
VL Viral load, the number of viral particles per ml blood
ART Antiretroviral therapy, here used to mean treatment with two NRTIs and an NNRTI or an “un-
boosted” PI
PMTCT Prevention of mother to child transmission
DRM drug resistance mutation
NRTI Drug of class nucleoside reverse transcriptase inhibitor
NNRTI Drug of class non-nucleoside reverse transcriptase inhibitor
PI Drug of class protease inhibitor, PIs can be used “unboosted” or “boosted” with an additional drug.
NVP Nevirapine, an NNRTI
sdNVP Single dose nevirapine
ZDV Zidovudine, also known as AZT, an NRTI
3TC, DDI, FTC, TDF Drugs of NRTI class
PP Post partem, used here for drugs which are added to sdNVP right after the mother has given birth
monotherapy during the third trimester of pregnancy (ZDV/sdNVP), or it can be combined
with additional drugs during and after labor up to one month postpartum (sdNVP/PP). It
can also be used alone (sdNVP) or combined with both (ZDV/sdNVP/PP), resulting in four
possible strategies.
Under the assumption that all resistance is due to standing genetic variation, it is straight-
forward to predict, at least qualitatively, the eﬀect of the four treatment options. Single dose
nevirapine plus two additional drugs (sdNVP/PP) is a three drug regimen, and similar to
standard antiretroviral therapy (ART), except that it only lasts a few days or weeks. We
therefore expect similar levels of drug resistance due to standing genetic variation. If only
NVP resistance is considered (and not resistance to the other two drugs), we expect to ﬁnd
somewhat lower levels than in the normal case, although the diﬀerence may not be large be-
cause resistance against NVP is more common than resistance to most other drugs. Treating
with only sdNVP is diﬀerent from starting ART, in that there is only one drug. The result
is that the ﬁtness of both wildtype and resistant virus will not be reduced as much as in the
normal case. Speciﬁcally, NVP resistant virus will have a relatively high ﬁtness during NVP
monotherapy. This high ﬁtness (Fm NVP)l e a d st oah i g he s t a b l i s h m e n tp r o b a b i l i t y( Pest)f o rSTANDING GENETIC VARIATION AND THE EVOLUTION OF DRUG RESISTANCE IN HIV 13
available resistance mutations. In fact, the establishment probability may be so high that in
virtually all patients that carry some NVP resistance before treatment, the resistant virus
will increase in frequency during NVP treatment.
An interesting treatment option is to start with a few weeks of ZDV monotherapy before
treating with a single dose of nevirapine. The ZDV treatment will reduce the population
size of the virus, Nu, so that the probability that NVP resistance is available and the copy
number of such resistant mutants if they are available will be lower by the time the patient is
treated with NVP. ZDV monotherapy ultimately leads to ZDV resistance, but the risk that
resistance mutations become established during a short course is small. ZDV monotherapy
reduces the viral load approximately three-fold [44]. Finally, adding ZDV treatment before
labor and two additional drugs during and after labor (ZDV/sdNVP/PP) will reduce both
the availability of NVP resistant virus and the establishment probability of such virus, which
should lead to an even lower probability that NVP resistance mutations from standing genetic
variation become established.
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Figure 3. The probability that resistance mutations are detected 6 to 8 weeks after
treatment with single dose nevirapine. Black crosses are data from single studies (the
number of studies is indicated in brackets at the top of the graph), black squares
with estimated standard error are percentages for all studies combined (the number
of patients that were used to calculate this percentage is indicated at the top of the
graph). Red circles with standard error are results from 1000 simulations and the
grey squares are analytical predictions. Parameter values as in table 1.
Comparison with data for single dose nevirapine. We identiﬁed 23 published studies
that reported on NVP resistance 6 to 8 weeks after women were treated with sdNVP. Several
of the studies directly compared two diﬀerent treatment options. We found at least three
studies for each of the four diﬀerent treatment options. An overview of the studies can be
found in table 4 in the supplementary material. For each study we recorded which of the
four treatment options was used and in how many of the patients NVP resistance mutations
were detected using simple Sanger (population) sequencing (we excluded studies that only
recorded deep-sequencing or allele-speciﬁc PCR results, as there were too few of those to
allow us to compare the treatment options). For each of the four treatment options, we also14 PLEUNI S. PENNINGS
calculated the overall probability that resistance mutations were detected in a patient (simply
by summing the number of patients with resistance and summing the total number of patients
in the studies). We found that sdNVP leads to detectable resistance mutations in 39% of
952 patients, ZDV/sdNVP leads to detectable resistance mutations in 22% of 888 patients,
adding two drugs during and after labor (sdNVP/PP) lead to detectable resistance mutations
in 7.8% of 372 patients and ZDV/sdNVP/PP lead to detectable resistance mutations in none
of 292 patients.
We now used these data, in combination with our previous parameter estimates, to estimate
the ﬁtness of a NVP resistant mutant during NVP therapy (Fm NVP) and the reduction of the
population size due to ZDV treatment (NZDV). We ﬁnd that Fm NVP ≈ 1.54 and that ZDV
reduces the eﬀective population size approximately two-fold (table 1 and ﬁgure 3). The results
show that a reduction in population size by ZDV monotherapy does reduce the probability
that NVP resistance mutations become established, but adding two drugs to sdNVP helps
much more. We also estimate the ﬁtness of the mutant during therapy with nevirapine and
two additional drugs and ﬁnd a slightly higher value than our previous estimate (1.025 vs
1.017), though these diﬀerences are not statistically signiﬁcant.
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Figure 4. The predicted probability of the establishment of drug resistance muta-
tions from standing genetic variation depending on the eﬀective population size and
the ﬁtness of the resistant mutant during therapy. Grey scales indicate the prob-
ability of the evolution of drug resistance due to standing genetic variation. Dots
indicate estimated parameter combinations for treatment with just sdNVP, with
ZDV monotherapy followed by sdNVP (ZDV/sdNVP), by sdNVP followed by two
additional drugs postpartum (sdNVP/PP) and with ZDV monotherapy followed by
sdNVP and two additional drugs postpartum ZDV/sdNVP/PP.
5.3. Interruption of therapy. During a treatment interruption, drugs are ﬁrst removed
from the body, which can take from a couple of hours to a several days or even weeks
([45, 46, 47]. With some delay, depending on the half-life of the drugs, the viral population
begins to grow, which is observed as an increase of viral load. Published data show that
after treatment is stopped, viral load quickly increases in almost all patients (e.g., [5]. Davey
et al [31] show that average viral load plateaus four weeks after treatment is interrupted.STANDING GENETIC VARIATION AND THE EVOLUTION OF DRUG RESISTANCE IN HIV 15
Garcia et al [48] and Trkola et al ([49]) both report that a plateau is reached between four
and eight weeks after treatment interruptions. An interruption is ended when treatment is
started again and viral load goes down, hopefully to undetectable levels. Figure 1 shows a
cartoon of the pharmacodynamics and population dynamics of a treatment interruption.
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Figure 5. Drug level (dashed line) and viral population size (solid line) during and
after a treatment interruption. Red bars indicate when drugs are taken.
Restarting therapy. If the length of a treatment interruption is so long that the pop-
ulation size is back to pretreatment level and mutation-selection-drift equilibrium is again
reached, the probability that resistance mutations become established when therapy is started
again will equal the probability that resistance mutations become established the ﬁrst time a
patient starts treatment, Psgv from equation 2. But if a treatment interruption is shorter than
that, it is hard to calculate the exact probability that resistance will evolve upon re-initiation
of therapy because neither population-dynamic, nor population-genetic equilibrium will have
been reached. The absence of the population-genetic equilibrium is most problematic if re-
sistance mutations are not very costly to the virus. However, for a costly mutation it takes
only on the order of 1/Crel generations to reach mutation-selection-drift equilibrium. The
absence of population-dynamic equilibrium is less problematic, because it is relatively easy
to predict the population size of the virus or to measure viral load. In the simulations, we
allow the population to grow exponentially until it reaches the baseline level. The resulting
population size can be plugged into equation 2 to get an estimate of the probability that
resistance mutations become established due to a treatment interruption.
Comparison with data for treatment interruptions. Using the parameter values
from the last two sections, we can predict the risk that resistance mutations become estab-
lished due to a treatment interruption of a certain length. We use the estimated ﬁtness of
the mutant virus during NVP therapy, and assume that the ﬁtness of the mutant in absence
of drugs is the same. With that value, we can calculate the ﬁtness of the wildtype in the
absence of drugs, because of the assumption that the cost of the resistance mutation is 5%.
The wildtype ﬁtness will determine how fast the virus grows in the simulations after treat-
ment is interrupted, and therefore how long it takes before the population size is back at the
pretreatment level. Speciﬁcally, we use Fwt =1 .62. In the simulations, the population size
plateaus after just 14 days, but Psgv reaches its expected value only after 60 days (ﬁgure 6).
We collected information from structured treatment interruption trials to test the predic-
tions. The probability that resistance mutations become established due to a single treat-
ment interruption was estimated for seven clinical trials with diﬀerent lengths of treatment
interruptions [50, 22, 51, 52, 53, 54, 20]. An overview of the trials can be found in table (sup-
plementary material). We ﬁrst calculated the risk under the assumption that all observed16 PLEUNI S. PENNINGS
resistance was due to treatment interruptions and then subtracted the estimated probability
that resistance mutations become established during therapy. The corrected values are shown
in ﬁgure 6. The data show that longer treatment interruptions indeed lead to a higher risk of
resistance. The risk plateaus around 37 days, which is consistent with the time it takes for
viral load to reach its equilibrium level (although the simulations suggest that the risk should
plateau later than the population size). The highest risk was found to be approximately 6%
per interruption, just like the risk of starting therapy for the ﬁrst time.
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Figure 6. Estimated probability that resistance mutations become established due
to a single treatment interruption. Bars are data from seven clinical trials, +/−
estimated standard error (see table 5, supplementary material), the red circles are
estimated from 1000 simulations, +/− estimated standard error the grey squares are
predictions using the average population size from the simulations and equation 2.
Parameters as in table 1.
6. Discussion
The main aim of our study was to understand and quantify the importance of standing
genetic variation for the evolution of drug resistance in HIV. We ﬁnd that the probability that
at least one resistance mutation becomes established due to standing genetic variation (Psgv)
depends on the kind of treatment chosen. Most clearly, it is much higher when treatment
is with sdNVP (which is monotherapy) than if treatment is with triple-drug combination
therapy. For standard combination therapy (ART), we use two diﬀerent data sources to
estimate the probability that resistance mutations from standing genetic variation become
established. In the ﬁrst part of this paper we used data on the number of patients in which
resistance was detected in the ﬁrst year of treatment versus later years. In the third part of
this paper we used data from clinical trials on treatment interruptions. In both cases, we
found that the probability that resistance mutations from standing genetic variation became
established was approximately 6%.
The importance of new mutations as compared to pre-existing mutations could be esti-
mated from the Margot et al ([35]) study. We estimated that the probability that a resistance
mutation becomes established during therapy (Pnew) is 3.7% per year, which means that pre-
existing mutations and new mutations are equally important after about one-and-a-half year
of treatment. Two of the interruption studies also provided estimates for Pnew,w h i c hw e r e
slightly higher (4.3% and 4.8% per year) than the estimate from the Margot et al [35] studySTANDING GENETIC VARIATION AND THE EVOLUTION OF DRUG RESISTANCE IN HIV 17
(see table 5). It is likely that some of the patients in these studies were not perfectly adherent
to treatment, so that our estimate of Pnew is inﬂated by patients who interrupted treatment.
This does not aﬀect our estimates of Psgv. However, it means that the relative importance
of pre-existing mutations is highest in completely adherent patients (because new mutations
are relatively unimportant for them) and lower in non-adherent patients (see [7] but see [11]).
A stochastic model was used to understand the eﬀect of standing genetic variation on
the evolution of drug resistance during HIV treatment. Four parameters are crucial to un-
derstand the role of standing genetic variation. Three of them determine the amount of
genetic variation that is available (eﬀective population size, mutation rate and cost of the
resistance mutations) and one determines how likely it is that the available mutations become
established (the absolute ﬁtness of the resistant virus during treatment).
The cost and the mutation rate are parameters that are diﬀerent for each speciﬁc mutation.
Together, they determine the expected frequency of the mutant in an untreated patient. For
example, in untreated patients the frequency of K103N was found to be lower than the
frequency of Y181C [7], suggesting that µ/Crel is lower for K103N. The costs for some of
the most important mutations (M184V, K103N) have been estimated and are between 1 and
10% ([38, 39, 40]. Throughout this paper we used a value of 5%.
The eﬀective population size in an untreated patient (Nu) determines how much variation
there is in the frequency of resistant mutants between patients. If Nu > 1/µ,t h ef r e q u e n c yi n
each patient will be very close to the expectation, µ/Crel,b u ti fNu < 1/µ,t h e r ew i l lb eal o t
of variation between patients, and in many patients no resistance mutations may be available
at all. Data suggest that in HIV the latter is the case (e.g., [7]), which means that, not every
single point mutation is created every generation in an HIV patient. Or, more precisely, each
mutation may be created, but not in a viral particle that is part of the eﬀective population
size. Mutations may even be detected in the blood stream of a patient, but may still be
irrelevant if the viral particles with the mutations are eliminated before they can infect a
CD4 cell.Nu also determines the number of resistant viral particles in a patient with a given
frequency of the mutant. With higher Nu,t h e r ew i l lb eah i g h e rn u m b e ro fr e s i s t a n tp a r t i c l e s ,
and this makes it more likely that resistance mutations become established when treatment
is started [11].
We ﬁnd that data are compatible with an 18-fold reduction of N due to ART and a two-fold
reduction of N due to ZDV monotherapy. The estimated reduction depends on the assumed
cost of mutations; if we assume that mutations are twice as costly, we would ﬁnd a reduction
that is twice as severe. Still, the reductions we ﬁnd are not nearly as severe as one may have
expected based on viral load reductions. During ART, VL may be reduced 1000-fold or more
(in the Margot ([35]) study from which we used the data, patients had a viral load of, on
average, 8 × 104 before treatment, whereas after 48 weeks of treatment, about 80% of the
patients had a viral load of less than 50, [55]). This discrepancy may be due to two eﬀects:
ﬁrstly, our estimate is an average for many patients and this average may be driven up by
patients in which the drugs do not work well, or who are not adherent to therapy so that
their VL does not go down as much as expected. Secondly, the relationship between eﬀective
population size and viral load may not be linear, so that a thousand-fold reduction in VL
may translate in only a twenty-fold reduction in eﬀective population size.
The fourth important parameter is the ﬁtness of the mutant virus during treatment (Fm),
which determines the establishment probability (Pest). Fm will depend on both the drugs
that are used and on the speciﬁc mutation. For example, the resistance mutation K103N is18 PLEUNI S. PENNINGS
more likely to become established during sdNVP than during triple-drug therapy, because
additional drugs reduce Fm (Fm ART <F m NVP). And during triple-drug therapy, K103N
is more likely to become established than Y181C (even though Y181C is present at higher
frequencies before treatment), likely because Fm ART is higher for K103N than for Y181C.
Starting of standard therapy. We assumed that the rate of evolution due to new
mutations is constant and that the establishment of a resistance mutation from standing
genetic variation leads to viral failure and is detected within one year of starting therapy.
Maybe the most convincing evidence for these assumptions comes from the Li et al [11]
study, where their ﬁgure 2 shows that (1) patients without detected pre-existing DRMs show
ac o n s t a n tr a t eo fe v o l u t i o no fr e s i s t a n c ea n d( 2 )p a t i e n t sw i t hd e t e c t e dp r e - e x i s t i n gD R M s
show an increased rate compared to the patients without pre-existing DRMs, but only in the
ﬁrst year of treatment. We used these assumptions to estimate the probability that resistance
mutations from standing genetic variation become established. However, the estimated role
of standing genetic variation may be a slight underestimate, because establishment of new
mutations should need some time so that Pnew would normally be somewhat lower in the ﬁrst
year of treatment. The observation that the eﬀect of standing genetic variation only lasts a
year, means that ﬁxation of a resistance mutation must take less than a year. This limits
possible values for NART and Fm ART to such values for which the ﬁxation time is less than
200 generations.
If resistance indeed evolves due to standing genetic variation in 6% of patients on standard
ART, then there is clearly room for improvement. Note that those 6% of patients have
already lost their ﬁrst treatment option shortly after having started treatment. They have
to switch to second-line treatment which is more expensive, usually more complicated (more
pills per day) and likely has more side eﬀects. It is therefore worth exploring ways to avoid
the establishment of resistance mutations from standing genetic variation. Figure 4 suggests
two options to reduce Psgv, by reducing the population size or by reducing the ﬁtness of
the resistant mutants. The ﬁrst may be achieved by ZDV monotherapy, as shown in the
section on PMTCT, whereas the second may be achieved by adding additional drugs to the
treatment. Obviously, triple-drug combination treatment is already standard for most HIV
patients, but it may be worth considering speciﬁcally which treatment options would be
best to prevent the evolution of resistance from standing genetic variation. This may mean,
for example, to add a fourth drug to the therapy in the ﬁrst couple of weeks of treatment.
Resistance to boosted PI’s is very uncommon, so they may be a good choice for starting
treatment, in combination with two or three other drugs.
Resistance due to sdNVP. Studying treatment with a single dose of nevirapine gives
us a unique opportunity to study the eﬀect of standing genetic variation, because treatment
is so short (only a few HIV generations) that we can assume that most or all resistance
mutations that are detected are from standing genetic variation. Data show that the risk
that resistance mutations become established due to such treatment is very high (39%).
We ﬁnd that this high probability can be explained entirely by selection on pre-existing
drug resistance mutations, because the ﬁtness of NVP resistant virus is probably very high
during NVP monotherapy. We estimate that its ﬁtness is approximately 1.5. The probability
that a resistance mutation becomes established can be reduced by either adding additional
drugs to lower the ﬁtness or by lowering the population size so that fewer mutants are
available. A study from Zambia [56] showed that the additional drugs even help to reduce
the establishment of NVP resistance mutations considerably if the additional drugs are givenSTANDING GENETIC VARIATION AND THE EVOLUTION OF DRUG RESISTANCE IN HIV 19
as a single dose (in stead of treatment for a couple of days or weeks). We did not include
this study in the overview, because there was only one study that looked at this treatment
option.
The results on ZDV/sdNVP/PP treatment (i.e., treatment with ZDV during pregnancy
and NVP plus two other drugs during labor) are surprising in that NVP resistance mutations
were not detected in any of the women who received this treatment, even though the model
would predict that mutations would be detected in 4% of the women. Most of the data on
this treatment option are from the Lallemant [57] paper (222 women). In this study, the
authors do ﬁnd some mutations that confer resistance to the NRTI’s in the study (in 2.3%
of the women). The same study also looked at women who were treated with ZDV/sdNVP
and also in these women the percentage with resistance mutations was very low (6.4%) and
much lower than the mean value for women who receive this treatment (22%). The reason
for the surprisingly low values of drug resistance in this study could be that the women in
the study had very low viral loads (median 2800). This probably also means that they have
al o we ﬀ e c t i v ep o p u l a t i o ns i z e . I tt h e r e f o r es e e m su n l i k e l yt h a tt h ee x t r e m e l yg o o dr e s u l t s
from the Lallemant study [57] can be replicated in other populations. However their results
still show that using additional drugs to reduce the population size and to reduce the ﬁtness
of the mutant may be a good strategy to reduce the probability that resistance becomes
established.
Treatment interruptions. Considering treatment interruptions, our model provides
several testable predictions. 1) resistance mutations are more likely to become established
after long treatment interruptions when viral loads are higher, 2) the risk that resistance
mutations become established due to a treatment interruption can not be larger than the
risk at the start of treatment, 3) treatment interruptions increase the risk of establishment
of resistance mutations even for drugs with short half-lifes.
Data from seven clinical trials show that indeed, longer interruptions increase the prob-
ability that resistance mutations become established (ﬁgure 6). Moreover, the estimated
probability appears to plateau after 37 days, which is similar to the time it takes for viral
load to reach its pretreatment level. This suggests that the risk of establishment of resistance
mutations is directly linked to the viral load when treatment is started again. The second
prediction was also found to hold: the estimated risk that resistance mutations from standing
genetic variation become established at the start of treatment was found to be similar to the
risk due to a long treatment interruption (6% in both cases). The third prediction also holds,
as data show that interruptions increase the risk of establishment of resistance mutations
even for PI based treatment [20, 51], where the “tail of monotherapy” cannot explain the
observations.
A potential problem with the data is that not only the length of the interruptions, but
also the length of treatment periods between the interruptions diﬀered between the seven
studies. The trials that were compared also diﬀered in the drugs that were used (see table
5i ns u p p l e m e n t a r ym a t e r i a l ) ,w h i c hm a k e sd i r e c tc o m p a r i s o nd i ﬃ c u l t . D e s p i t ea l lt h e s e
limitations, it becomes clear that longer interruptions carry a higher risk of evolution of
resistance than shorter interruptions.
If interruptions lead to the establishment of resistance mutations only due to the “tail of
monotherapy”, as is usually assumed in the HIV literature [24, 25, 18], we would predict that:
4) treatment interruptions increase the risk that resistance mutations become established only
for drugs with long half-lifes, 5) the risk that resistance mutations become established due20 PLEUNI S. PENNINGS
to a treatment interruption is unrelated to the risk at the start of treatment and 6) the
largest risk would be due to an interruption with a length that is exactly the time it takes
for the last drug to lose its eﬀect on the wildtype virus. All of these predictions do not hold.
This is not to say that the “tail of monotherapy” is not important at all. But it does show
that on its own, the “tail of monotherapy” cannot explain the risk that resistance mutations
become established due to treatment interruptions. When one considers possible intervention
strategies, this may be good news. If treatment interruptions are risky because of restarting
rather than stopping therapy, this would give doctors a possibility to reduce the risk that
resistance mutations become established even after a patient has already stopped taking his
or her drugs. The establishment of resistance mutations at re-initiation of treatment may be
avoided by pretreatment (such as with ZDV) to reduce the availability of mutations or by
using more drugs or higher doses in the ﬁrst weeks of treatment to reduced the establishment
of pre-existing mutations.
General remarks. We have used a population-dynamic and population-genetic model
to study several patterns of drug resistance in HIV. The model explains why resistance
mutations are likely to become established in the ﬁrst year of standard treatment, in women
who are treated with a single dose of nevirapine and in patients who interrupt treatment. In
all three cases, standing genetic variation can explain the observations.
Our results illustrate that for adaptive evolution to happen, selection and the creation of
new variation need not happen at the same time, if selection can work on standing genetic
variation. In the case of antiretroviral treatment, this means that insuﬃcient drug levels
(which allow for replication and selection at the same time) are not a necessary condition for
the evolution of drug resistance. This result about time-heterogeneous drug levels is similar
to the result on heterogeneity in space by Kepler and Perelson [58], who showed that genetic
variation may be created in compartments where drugs cannot penetrate whereas selection
happens in other compartments.
Our model provides a simple and quantitative explanation for why resistance is less likely
to evolve when patients are treated with multiple drugs in stead of just one drug. Additional
drugs reduce the ﬁtness of a mutant that is resistant against one drug, and therefore the
establishment probability of such a resistant mutant. In addition, additional drugs reduce
the population size of the virus and thereby the creation of new resistance mutations. This
means that there will be fewer resistance mutations with lower establishment probabilities,
together leading to a strong reduction in the probability that resistance evolves. In newer
therapies with boosted PIs, drug resistance has become very rare [6], which may be because
boosted PIs are so strong that no single mutation can lift the virus’ ﬁtness above 1.
The model in this study may be relevant to other diseases than HIV. For example, the
evolution of resistance is a problem in chronic myeloid leukemia (CML) which is a cancer of
white blood cells. A recent study suggested that the probability that drug resistance evolves
in CML goes down with time because the population size of the cancer goes down with time
[59].
Resistance is also a problem in tuberculosis (TB), and in TB it is also known that treatment
interruptions increase the risk of evolution of resistance [60]. This eﬀect may also be due to
an increased population size during the interruptions. In general, stopping treatment may
be risky in cases where treatment has to be started again, which is always the case for HIV
and often for TB. Each time therapy is started, resistance mutations from standing geneticSTANDING GENETIC VARIATION AND THE EVOLUTION OF DRUG RESISTANCE IN HIV 21
variation may become established, and even if this risk is only a few percent it adds up
quickly when patients interrupt treatment regularly.
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9. Supplementary material
9.1. Model. The model describes population dynamics and population genetics of a pan-
mictic virus population in a single patient. Only virus in infected cells is considered and the
dynamics of free virus and uninfected cells are ignored. The total number of cells that can be
infected is limited to K, the carrying capacity. Because the life cycle of the virus is simpliﬁed
to just one step in which infected cells “give birth” to infected cells, all drugs have the same
eﬀect: they reduce the number of cells that can be infected by the virus in an infected cell.
We will refer to the infected cells by the virus they are infected with.
When patients fail therapy, this is often due to virus that is resistant against just one
drug even if the patient was treated with three drugs (as described in the Introduction). We
therefore assume in our model that there are just two types of viruses: wildtype virus that
is susceptible to all drugs and resistant virus that is resistant against one of the drugs in the
regimen of the patient. We assume that prior to establishment of single drug-resistant virus
(hereafter: resistant virus), there is no virus present that is resistant against more than one
drug. We only focus on the probability that single drug-resistant virus becomes established.
The resistant type has a growth rate larger than 1 even in the presence of drugs, but in
the absence of drugs it is less ﬁt than the wildtype. Initially the population consists of only
wildtype virus, resistant virus can be created by mutation. Absolute ﬁtnesses are determined
for wildtype and resistant virus, in the absence of drugs (denoted by u for untreated) and
during treatment (either ART or NVP). These ﬁtnesses are absolute ﬁtnesses, which are
equivalent to the reproductive ratio, or the expected number of cells a viral particle would
infect in a completely susceptible population of host cells. Without drugs, wildtype virus is
ﬁtter than resistant virus, so that the population will always be dominated by wildtype virus.
During treatment, resistant virus is ﬁtter than wildtype, so that the population will ultimately
become dominated by resistant virus. However, if evolution is mutation-limited, it can take
al o n gt i m eb e f o r et h ee q u i l i b r i u mw i t hr e s i s t a n tv i r u si sr e a c h e d . O n eo ft h es u c c e s s e so f
combination therapy is to make this waiting time much longer than with monotherapy.
The relative cost or selective disadvantage is deﬁned as Crel =( Fwt u −Fm u)/(Fwt u), or,
in other words, how much less ﬁt resistant virus is in the absence of drugs, relative to the
wildtype. As will be shown later, the ﬁtness of the wildtype with drugs is not important in
the current model (although we do have to determine its value for the simulations).
If the average ﬁtness of the viral population is larger than 1, the viral population grows
exponentially until it reaches the carrying capacity (K), at which point the population stops
growing and stays stable. If the average ﬁtness of the population is below 1, the population
shrinks until it reaches NLAT/(1 − Fwt), where NLAT is a ﬁxed number of particles which
is added to the population each generation. This reﬂects the latently infected cells in an
HIV infected patient. These latently infected cells have very long half-lifes and function as
a reservoir for the HIV population. Because of these cells, the virus population does not die
out, even if therapy is very successful and there is (almost) no replication.
Simulation details. Time is counted in generations. Each generation is split in 10 time-
steps. At each time step, each viral particle has a probability of 1/10 to be chosen to reproduce
and die. The expected life-time of a viral particle is therefore 1 generation and this is the same
for wildtype and resistant virus. All particles that are chosen to reproduce at a given time-step
die and are replaced by their oﬀspring (i.e. newly infected cells). The number of oﬀspring is
equal to [number of chosen wildtype particles]∗[Fwt]+[number of chosen resistant particles]∗
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instead of using the number directly, we take a random number from the Poisson distribution
with the expected number as the mean. If adding of the new oﬀspring to the population would
lead the population size to be higher than K,w ea d df e w e ri n d i v i d u a l ss ot h a tt h ep o p u l a t i o n
size will be exactly K. The new oﬀspring can be either wildtype or resistant. It is assigned
at y p ea tr a n d o m ,w i t hp r o b a b i l i t y
[number of chosen wildtype particles] ∗ [Fwt]
[number of chosen wildtype particles] ∗ [Fwt]+[ n u m be ro fc h o s e nr e sp a r t i c l e s ]∗ [Fres]
to be wildtype, and resistant otherwise. This is a standard procedure (also used in [14])
The choice of 10 time-steps per generation is a compromise between the speed of simulating
discrete generations and the reality of continuous replication.
Mutation occurs only from wildtype to resistant. Back-mutation to wildtype is ignored.
The number of mutations in a generation depends on the (per particle and per generation)
mutation rate, µ,a n dt h en u m b e ro fn e w l yc r e a t e di n f e c t e dc e l l s ,w h i c hi nt u r nd e p e n d so n
ﬁtness and population size.
Analytical calculation of the ﬁxation probability. To calculate the probability that
resistance mutations become established when treatment is started (either for the ﬁrst time
or after an interruption), there are two possibilities. When the relative cost of resistance in
the absence of drugs, the ﬁtness of the resistant virus with drugs and the viral population
size are all known, we can use the theory from [14] to calculate the probability that resistance
mutations from the standing genetic variation become established. Alternatively, if the num-
ber of copies of the resistant virus and the ﬁtness of resistant virus are known, it is possible
to calculate the probability that at least one of these copies will survive, in which case the
population becomes resistant. For the latter, we need the probability that a single resistant
mutant spreads in the population and ultimately goes to ﬁxation, as opposed to being lost
due to genetic drift. In the current model, individuals (viral particles in infected cells) will
“produce” a Poisson distributed number of newly infected cells (we call these oﬀspring). The
mean number of oﬀspring, λ,d e t e r m i n e st h ep r o b a b i l i t yt h a tal i n e a g ed i e so u to rs u r v i v e s .
Usually, it is assumed that the mean number of oﬀspring of a genotype depends on its ﬁtness
relative to the mean ﬁtness of the population. However, when a patient takes drugs, the
population size of the virus will be much lower than the carrying capacity, so that there is
eﬀectively no competition between resistant and wildtype virus. The mean number of oﬀ-
spring, λ,t h e r e f o r ed o e sn o td e p e n do nt h er e l a t i v eﬁ t n e s s ,b u ts i m p l ye q u a l st h ea b s o l u t e
ﬁtness of the resistant virus. In 1927, Haldane [32] showed that the relationship between the
mean number of oﬀspring (λ)a n dt h eﬁ x a t i o np r o b a b i l i t yi s
(6) λ = −
log(1 − Pfix)
Pfix
=1+
Pfix
2
+
P 2
fix
3
+
P 3
fix
4
+
P 4
fix
5
+ O(P
5
fix)
Traditionally, the ﬁxation probability is calculated using the selection coeﬃcient, sb =
Fres−Fwt
Fwt ,i n s t e a do ft h ee x p e c t e dn u m b e ro fo ﬀ s p r i n g ,λ.I n a p o p u l a t i o n w i t h s t a b l e p o p -
ulation size and competition between genotypes this is ﬁne because λ =1+sb,b u ti nt h e
current model, this does not hold and sb is irrelevant.
If λ − 1i ss m a l l ,as i m p l ea p p r o x i m a t i o nf o rt h eﬁ x a t i o np r o b a b i l i t yi s :
(7) Pfix ≈ 2(λ − 1)28 PLEUNI S. PENNINGS
When λ is larger, Haldanes equation needs to be solved numerically using more terms of
the Taylor expansion.
9.2. Data from clinical trials. Starting standard therapy. The probability that resis-
tance mutations from standing genetic variation become established at the start of therapy
was estimated from a data set that was published in [35], see table 3 for the raw data. The
study reported the number of patients where resistance was detected in the ﬁrst, second
and third year of treatment, for two treatment groups and for three categories of resistance
mutations. Because in each case only the ﬁrst resistance mutation in a given patient was
recorded, the data for the three diﬀerent resistance classes could not be analyzed separately.
A saturated model was ﬁtted using R [61] after which non-signiﬁcant interactions were re-
moved. It was found that the probability that resistance mutations became established did
not diﬀer signiﬁcantly between the two treatment groups (p=0.26) and also not between year
2 and year 3 (p=0.78). However, there was a clear diﬀerence between year 1 and the other
two years (p<10−5). The average risk per year in year 2 and 3 was 3.7%, whereas the
average risk in year 1 was 9.5%. The diﬀerence between year 1 and the other 2 years was
5.8%, which could be due to the standing genetic variation before treatment started.
Single dose nevirapine. We searched the web of science (ISI) database for published
studies on single dose nevirapine and resistance. We limited ourselves to studies that reported
the fraction of women that had detectable resistance at 4 to 6 weeks postpartum using
standard sequencing. An overview of the studies can be found in table 4.
Interruption studies. Seven studies were identiﬁed that reported on clinical trials in
which patients interrupted treatment multiple times for a ﬁxed length of time (i.e., all patients
in the trial were on the same schedule) and which tested genotypic resistance on plasma
samples of all patients in which treatment failed (and ideally of all patients) before and
after the trial. Characteristics of the seven studies can be found in table 5 (supplementary
material). The shortest interruption length was two days and the longest 60 days. If possible,
we removed patients which had evidence of resistance before the trial started. In all but one
of the studies, patients were on traditional triple-drug regimens (NNRTI or PI based with
two NRTIs). Only in the Staccato study some patients were on a boosted PI regimen [50].
These patients were taken out of the analysis because resistance seems to evolve much slower
in regimens with boosted PI’s compared to NNRTI and unboosted PI regimens [62]. In two
trials, the interruptions had varying lengths [51, 52], in which case we used the mean length
of the interruptions for the plot (these points are in grey in the plot, see ﬁgure 6).
For each study, the fraction of patients (F)w h i c hd i dn o ta c q u i r ea n yr e s i s t a n c em u t a t i o n s
during the trial was calculated. The number of treatment interruptions (T)w h i c hw e r e
relevant for the resistance data was calculated. For example, if genotypic resistance tests were
done on samples that were obtained during treatment interruption 4, it was assumed that any
resistance had occurred due to treatment interruption 1, 2 or 3 so that T =3 .F u r t h e r m o r e
it was assumed that each treatment interruption (TI ) contributed equally to the probability
that resistance mutations became established. The probability (P)t h a tr e s i s t a n c em u t a t i o n s
became established due to a single interruption was calculated as follows:
(8) F =( 1− P)
T ⇒ P =1− F
1/T
Two of the studies also allowed for an estimation of the risk that resistance mutations
became established during continuous treatment [53, 54, 22]. We ﬁnd a rate of evolution ofSTANDING GENETIC VARIATION AND THE EVOLUTION OF DRUG RESISTANCE IN HIV 29
resistance of 4.3% and 4.8% per year (see table 5). Using the mean of these two rates, we
can estimate the probability that resistance mutations became established during the time
on treatment in each of the trials and we corrected the estimated risk of an interruption by
subtracting the probability that resistance mutations became established during treatment.
9.3. Supplementary tables.30 PLEUNI S. PENNINGS
9.4. Figure legends. Figure 1
The probability that resistance is detected for the ﬁrst time in the ﬁrst, second or third
year of treatment, given that it was not detected until then. The bars are the estimates from
the Margot et al ([35]) dataset. The red dashed area reﬂects the inferred probability that
resistance mutations from standing genetic variation become established. The grey squares
are values calculated using equations 2 and 4. The red circles are estimated from 1000
simulations. Parameters as in table 1.
Figure 2a
Continuous line: combinations of population size before treatment (Nu)a n dﬁ t n e s so f
mutant virus during therapy (Fm ART that lead to the observed probability that resistance
mutations from standing genetic variation become established (Psgv =0 .058). Dashed line:
combinations of population size during treatment (NART) and ﬁtness of mutant virus dur-
ing therapy (Fm ART that lead to the observed probability that resistance mutations from
standing genetic variation become established (Psgv =0 .058). Open dot: Nu =2 0 0 0a n d
Fm ART =1 .017, closed dot: NART =1 0 8 ,Fm ART =1 .017.
Figure 2b
Probability that a patient has any pre-existing DRMs before the start of therapy for
diﬀerent population sizes, and µ =5× 10−5. Open dot: Nu =2 0 0 0
Figure 3
The probability that resistance mutations are detected 6 to 8 weeks after treatment with
single dose nevirapine. Black crosses are data from single studies (the number of studies is
indicated in brackets at the top of the graph), black squares with estimated standard error
are percentages for all studies combined (the number of patients that were used to calculate
this percentage is indicated at the top of the graph). Red circles with standard error are
results from 1000 simulations and the grey squares are analytical predictions. Parameter
values as in table 1.
Figure 4
The predicted probability of the establishment of drug resistance mutations from standing
genetic variation depending on the eﬀective population size and the ﬁtness of the resistant
mutant during therapy. Grey scales indicate the probability of the evolution of drug resis-
tance due to standing genetic variation. Dots indicate estimated parameter combinations for
treatment with just sdNVP, with ZDV monotherapy followed by sdNVP (ZDV/sdNVP), by
sdNVP followed by two additional drugs postpartum (sdNVP/PP) and with ZDV monother-
apy followed by sdNVP and two additional drugs postpartum ZDV/sdNVP/PP.
Figure 5
Drug level (dashed line) and viral population size (solid line) during and after a treatment
interruption. Red bars indicate when drugs are taken.STANDING GENETIC VARIATION AND THE EVOLUTION OF DRUG RESISTANCE IN HIV 31
Table 3. Number of patients with at least one resistance mutation detected by the
end of the ﬁrst, second and third year of NNRTI-based antiretroviral therapy. Data
from [35].
Year Group Resistant Not Resistant
1 TDF 35 264
2 TDF 8 256
3 TDF 9 247
1 d4T 22 279
2 d4T 10 269
3 d4T 11 25832 PLEUNI S. PENNINGS
Table 4. Overview of clinical trials with single dose nevirapine which reported the
number of patients with nevirapine resistance detected 6 to 8 weeks after treatment.
Reference and name trial Number of
patients
Treatment Treatment code Est. prob of es-
tablishment of
resistance
Remarks
Eshleman 2005 [63],
Malawi
65 sdNVP sdNVP 0.69
Eshleman 2005 [63],
Uganda
241 sdNVP sdNVP 0.26
Farr 2010 [64], Malawi 65 sdNVP sdNVP 0.34
Hudelson 2010 [65],
Uganda
30 sdNVP sdNVP 0.43
Jackson 2000 [66], Uganda 15 sdNVP sdNVP 0.20
Kassaye 2007 [67], Zim-
babwe
32 sdNVP sdNVP 0.35
Lee 2005 [68], Zimbabwe 32 sdNVP sdNVP 0.34
Loubser 2006 [69], South
Africa
44 sdNVP sdNVP 0.54 Results only for
K103N mutation
Ly 2007 [70], Cambodia 35 sdNVP sdNVP 0.23
Martinson 2009 [71], South
Africa, HIVNET 012
108 sdNVP sdNVP 0.38
Martinson 2009 [71], South
Africa, HIVNET 012
193 sdNVP sdNVP 0.46
McIntyre 2009 [72], South
Africa
74 sdNVP sdNVP 0.59
Rajesh 2010 [73], India 12 sdNVP sdNVP 0.33
Toni 2005 [74] , Ivorycoast 29 sdNVP sdNVP 0.21
Farr 2010 [64], Malawi 120 sdNVP + 7 days
3TC/ZDV
sdNVP/PP 0.017
McIntyre 2009 [72], South
Africa
164 sdNVP + 4 days
3TC/ZDV
sdNVP/PP 0.097
McIntyre 2009 [72], South
Africa
168 sdNVP + 7 days
3TC/ZDV
sdNVP/PP 0.073
Chaix 2007
[75], Ivorycoast,
ANRS/Ditrame Plus
63 ZDV from 36 weeks +
sdNVP
ZDV/sdNVP 0.33
Chalermchokcharoenkit
2009 [76], Thailand
190 ZDV 3rd trimester +
sdNVP
ZDV/sdNVP 0.18
Chi 2009 and 2007 [77, 56],
Zambia
166 ZDV 3rd trimester +
sdNVP
ZDV/sdNVP 0.25
Lallemant 2009 [57], Thai-
land, PHPT2
222 ZDV 3rd trimester +
sdNVP
ZDV/sdNVP 0.064
Ly 2007 [70], Cambodia 16 ZDV from 28 weeks +
sdNVP
ZDV/sdNVP 0.19
Shapiro 2006 [78],
Botswana
155 ZDV from 34 weeks +
sdNVP
ZDV/sdNVP 0.45
Van Zijl 2008 [79], South
Africa
76 ZDV from 34 weeks +
sdNVP
ZDV/sdNVP 0.17
Arrive 2010 [80], Cam-
bodia/Ivorycoast/South
Africa, TEmAA ANRS
12109
33 ZDV from enrollment
+s d N V P+1w e e k
TDF/FTC
ZDV/sdNVP/PP 0.0
Dabis 2009 [81], Cam-
bodia/Ivorycoast/South
Africa, TEmAA ANRS
12109
37 ZDV from enrollment
+s d N V P+1w e e k
TDF/FTC
ZDV/sdNVP/PP 0.0
Lallemant 2009 [57], Thai-
land, PHPT4
222 ZDV 3rd trim +
sdNVP + 1 month
ZDV/DDI
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Table 5. Overview of clinical trials with structured treatment interruptions which
reported the number of patients with at least one drug resistance mutation detected.
Reference and name
trial
%o n
PI
Number
of pa-
tients
Patients
excluded
Patients
with
genotypic
resistance
Fraction
not re-
sistant
at end of
trial
TI’s
rele-
vant for
calcula-
tion
Length
of TI
(days)
Treatment
period
(days)
Est. prob
of evo-
lution of
resistance
per TI
Corrected
prob of
evolu-
tion of
resistance
Interruption arms
Reynolds 2009
and 2010 [54, 53],
Uganda FOTO arm
2% 57 1( n og e n o -
type)
4 52/56 72 2 5 0 0
Ananworanich
2003 [50], Staccato
WOWO arm
0% 36 22 (on
boosted
PI) 2 (had
resistance
before
trial)
3 9/12 17 7 7 0.02 0.02
Reynolds 2009
and 2010 [54, 53],
Uganda WOWO
arm
6% 32 3( l e f tt h e
trial)
9 20/29 18 7 7 0.02 0.02
Yerly 2003 [20] ,
SSITT trial
100% 87 4( l o s tt o
follow-up)
3( a l r e a d y
resistance
before
trial)
11 69/80 4 14 56 0.04 0.03
Hoen 2005 [51],
ANRS 100 Prim-
stop trial
100% 26 4( r e -
sistance
before
trial) 1
(resistance
in ﬁrst TI)
2 19/21 2 14, 28
(mean
21)
84 0.05 0.04
Palmisano 2007
[52], ISS PART
25% 136 16 (es-
timated
number
that had
resistance
before)
22 98/120 3 28,
28, 56
(mean
37)
91 0.07 0.06
Danel 2009 [22],
Ivory Coast NCT
00158405
10% 325 10 (no
genotypes)
76 239/315 4 60 91 0.07 0.06
Continuous arms
Reynolds 2009
and 2010 [54, 53],
Uganda continuous
arm
2% 51 0 3 48/51 – – 504 – 0.043/year
Danel 2009 [22],
Ivory Coast NCT
00158405
15% 110 3( n og e n o -
types)
10 97/107 – – 728 – 0.048/year